欧美国产日韩在线免费观看-欧美日韩成人激情一区二区-欧美久久综合一区二区-亚洲av寂寞少妇久久

Thrombopoietin （TPO） is the primary cytokine responsible for regulating platelet production by stimulating the proliferation and differentiation of megakaryocytes, the bone marrow cells that produce platelets. TPO binds to the thrombopoietin receptor （TPO-R or c-Mpl） on hematopoietic stem cells （HSCs） and megakaryocyte progenitors, activating signaling pathways such as JAK2/STAT5, PI3K/AKT, and RAF-1/MAPK, which promote platelet production and maintain hematopoietic stem cell populations.
TPO and its receptor agonists （TPO-RAs） are widely used to treat immune thrombocytopenia （ITP）, chemotherapy-induced thrombocytopenia, and thrombocytopenia associated with chronic liver disease or myelodysplastic syndromes （MDS）37. Recombinant human TPO （rhTPO） and synthetic TPO-RAs （e.g., romiplostim, eltrombopag, avatrombopag） have shown efficacy in increasing platelet counts in clinical settings.